Trick, or treat? FDA plans Halloween adcomm for Ipsen’s second chance at rare disease drug
An oft-maligned rare bone disease program at Ipsen is going to get a closer look from regulators on a day that’s proven to be mighty …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
